

Edgar Filing: ADVANCED PHOTONIX INC - Form 10QSB

ADVANCED PHOTONIX INC
Form 10QSB
February 06, 2002

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-QSB

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended December 23, 2001

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file no. 1-11056

ADVANCED PHOTONIX, INC.

Incorporated pursuant to the Laws of Delaware

IRS Employer Identification No. 33-0325826

1240 Avenida Acaso, Camarillo, CA 93012

(805) 987-0146

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

On February 1, 2002, 12,211,648 shares of Class A Common Stock, \$.001 par value, and 31,691 shares of Class B Common Stock, \$.001 par value, were outstanding.

ADVANCED PHOTONIX, INC.

INDEX

	PAGE
PART I FINANCIAL INFORMATION	
Item 1. Financial Statements (Unaudited)	

Edgar Filing: ADVANCED PHOTONIX INC - Form 10QSB

Balance Sheet at December 23, 2001	3 - 4
Statements of Operations for the three and nine month periods ended December 23, 2001 and December 24, 2000	5
Statements of Cash Flows for the nine month periods ended December 23, 2001 and December 24, 2000	6
Notes to Financial Statements	7 - 8
Item 2. Management's Discussion and Analysis	9 - 11
PART II OTHER INFORMATION	12
SIGNATURES	13

-2-

ADVANCED PHOTONIX, INC.

BALANCE SHEET
AT DECEMBER 23, 2001
(UNAUDITED)

ASSETS	
CURRENT ASSETS	
Cash and cash equivalents	\$ 4,509,000
Accounts receivable, less allowance of \$6,000	1,128,000
Inventories	2,310,000
Prepaid expenses and other current assets	134,000
Total Current Assets	8,081,000

EQUIPMENT AND LEASEHOLD IMPROVEMENTS, at cost	3,663,000
Less accumulated depreciation and amortization	(2,971,000)
Total Equipment and Leasehold Improvements	692,000

OTHER ASSETS	
Goodwill, net of accumulated amortization of \$344,000	491,000
Patents, net of accumulated amortization of \$40,000	24,000
Other	24,000
Total Other Assets	539,000

TOTAL ASSETS	\$ 9,312,000
=====	

See notes to financial statements.

-3-

ADVANCED PHOTONIX, INC.

BALANCE SHEET
AT DECEMBER 23, 2001
(UNAUDITED)

LIABILITIES AND STOCKHOLDERS' EQUITY	
CURRENT LIABILITIES	
Accounts payable	\$ 219,000
Accrued expenses:	
Salaries and employee benefits	198,000
Warranty	23,000

Total Current Liabilities	440,000

COMMITMENTS AND CONTINGENCIES	
Class A redeemable convertible preferred stock, \$.001 par value; 780,000 shares authorized; 40,000 shares issued and outstanding	32,000
SHAREHOLDERS' EQUITY	
Preferred stock, \$.001 par value; 10,000,000 shares authorized; 780,000 shares designated Class a redeemable convertible; no shares issued and outstanding	--
Class A common stock, \$.001 par value; 50,000,000 shares authorized; 12,211,648 shares issued and outstanding	12,000
Class B common stock, \$.001 par value; 4,420,113 shares authorized; 31,691 shares issued and outstanding	--
Additional paid-in capital	26,576,000
Accumulated Deficit	(17,748,000)

Total Shareholders' Equity	8,872,000

TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	\$ 9,312,000
	=====

See notes to financial statements.

-4-

Edgar Filing: ADVANCED PHOTONIX INC - Form 10QSB

ADVANCED PHOTONIX, INC.

STATEMENTS OF OPERATIONS
(UNAUDITED)

	Three Months Ended		December 25, 2000
	December 23, 2001	December 24, 2000	
SALES	\$1,629,000	\$1,788,000	\$5,230,000
Cost of goods sold	975,000	1,146,000	2,230,000
GROSS PROFIT	654,000	642,000	2,000,000
Research and development expenses	102,000	168,000	
Marketing and sales expenses	220,000	198,000	
General and administrative expenses	282,000	251,000	
Acquisition investigation expenses	(14,000)	--	
INCOME (LOSS) FROM OPERATIONS	64,000	25,000	(1,230,000)
OTHER INCOME			
Interest income	34,000	100,000	
Other, net	--	--	
TOTAL OTHER INCOME	34,000	100,000	
NET INCOME (LOSS)	\$ 98,000	\$ 125,000	\$ (1,230,000)
Basic and Diluted Earnings (Loss) Per Share	\$.01	\$.01	
Weighted Average Number of Common Shares Outstanding	12,243,000	12,231,000	12,231,000

See notes to financial statements.

-5-

ADVANCED PHOTONIX, INC.

STATEMENTS OF CASH FLOWS
(UNAUDITED)

For the nine month period ended

December 23,

Edgar Filing: ADVANCED PHOTONIX INC - Form 10QSB

CASH FLOWS FROM OPERATING ACTIVITIES

Net Income (Loss)	(\$ 55,000)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:	
Depreciation	151,000
Amortization	25,000
Write off of prepaid acquisition costs, net of \$200,000 cash expended	430,000
Changes in assets and liabilities:	
Short-term investments	1,082,000
Accounts receivable	39,000
Inventories	(583,000)
Prepaid expenses and other current assets	--
Accounts payable and accrued expenses	(83,000)

Net cash provided by operating activities	1,006,000

CASH FLOWS FROM INVESTING ACTIVITIES

Capital expenditures	(407,000)

Net cash used by investing activities	(407,000)

CASH FLOWS FROM FINANCING ACTIVITIES

Proceeds from exercise of stock options	3,000

Net cash provided by financing activities	3,000

NET INCREASE IN CASH & CASH EQUIVALENTS	602,000
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	3,907,000

CASH AND CASH EQUIVALENTS AT END OF PERIOD	\$ 4,509,000
	=====

See notes to financial statements.

-6-

ADVANCED PHOTONIX, INC.
NOTES TO FINANCIAL STATEMENTS
December 23, 2001
(UNAUDITED)

NOTE 1 - BASIS OF PRESENTATION

The accompanying unaudited financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-QSB and Article 10 of Regulation S-X and Regulation S-B. Accordingly, they do not include all of the information and notes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting

Edgar Filing: ADVANCED PHOTONIX INC - Form 10QSB

of normal recurring adjustments) necessary for a fair presentation have been included. Operating results for the nine month period ended December 23, 2001, are not necessarily indicative of the results that may be expected for the fiscal year ending March 24, 2002. For further information, refer to the financial statements and notes thereto included in the Advanced Photonix, Inc. Annual Report on Form 10-KSB for the fiscal year ended March 25, 2001.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Net Income (Loss) Per Share: Net income (loss) per share is based on the weighted average number of common shares outstanding. Such weighted average shares were approximately 12,241,000 at December 23, 2001 and 12,180,000 at December 24, 2000. Net income (loss) per share calculations are in accordance with Statement of Financial Accounting Standards ("SFAS") No. 128, "Earnings per Share" (SFAS 128). Accordingly, "basic" net income (loss) per share is computed by dividing net income (loss) by the weighted average number of shares outstanding for the year. "Diluted" net income (loss) per share has not been presented in the financial statements as the impact is either not material or anti-dilutive.

-7-

NOTE 2 - Continued

The following stock options granted to Company employees and directors were excluded from the calculation of earnings per share in the financial statements because they were anti-dilutive:

No. of Shares Underlying Options	Exercise Price Per Share
4,000	.6875
88,000	.7500
238,673	.8000
50,000	1.0000
13,900	1.1875
59,200	1.2500
4,000	1.5000
4,000	1.6250
44,000	1.8750
35,600	2.5000
8,000	3.0000
500	3.0940
400,000	3.1875
25,000	5.3440

974,873	
=====	

Edgar Filing: ADVANCED PHOTONIX INC - Form 10QSB

Inventories: Inventories consist of the following:

	December 23, 2001
Raw materials	\$ 753,000
Work in progress	1,213,000
Finished products	344,000

	\$ 2,310,000
	=====

-8-

Item 2. Management's Discussion and Analysis

RESULTS OF OPERATIONS

The Company's net sales for the third quarter ("Q3 02") and nine month period ("YTD 02") ended December 23, 2001, were \$1.6 million and \$5.3 million, respectively. As compared to the third quarter of the prior year ("Q3 01"), net sales decreased by 9%, while year to date net sales increased by 1% over the same nine month period of the prior year ("YTD 01").

The decrease in net sales for the quarter was primarily due to lower volume in military aerospace and industrial sensing revenues and was partially offset by increases in the medical equipment and imaging markets, as compared to the same period in the prior year. Although quarterly sales to the military and industrial sensing markets declined by 22% and 5% respectively, sales to the medical markets increased by 18% over Q3 01. On an ongoing basis, the Company has continued to compete for military aerospace contracts, which are dependent on funding from the United States government. Year to date, military revenues have increased 8% over the prior year and represent 37% of total revenues. Although military revenues have fluctuated significantly in the past, the Company anticipates continued increases in military aerospace revenues as government spending increases and additional government military programs are approved.

For both the quarter and year to date, the Company has continued to recognize increases in the medical equipment and imaging markets. As compared to the prior year, sales to the medical markets have increased by 18% and 50% for the quarter and year to date periods respectively. Total sales to the medical markets accounted for 19% of total revenues for the third quarter of 2002 and for 18% of total revenues for the first three quarters of 2002, as compared to 15% and 12% for the same periods in the prior year. Continuous improvements made by medical

Edgar Filing: ADVANCED PHOTONIX INC - Form 10QSB

equipment manufacturers in technology and design have resulted in increased demand for the Company's products in those markets. The Company expects to see continued increases in sales to the medical markets as it realizes increased demand for its custom designed products and its ability to respond to the demands of the rapidly changing marketplace.

Cost of sales decreased by \$171,000 (15%) in the third quarter of 2002 and by \$253,000 (8%) for the year to date period as compared to the same periods of the prior year. Throughout the year, the Company has continued to realize improved gross margins as a result of measures taken to cut costs and reduce production overhead. The improved efficiencies have resulted in a gross profit margin of 40% for the third quarter of 2002, an increase of 4 percentage points over the prior year and a gross profit margin of 43% for the year to date period, an increase of 5 percentage points over the same period in the prior year.

Research and development costs decreased by \$66,000, or 39%, in the third quarter of 2002 as compared to the third quarter of 2001. Year to date, research and development costs have decreased by \$47,000, or 12%, as compared to the prior year. The reduction in research and development expenses are primarily due to variable expenditures associated with current development projects, including reduced material costs and overhead rates as compared to the prior year. As described in the past, research and development costs may continue to vary significantly, due to the level of activity associated with development contracts as well as the number and complexity of new process and product development projects, the qualification of new process developments and customer evaluation and acceptance of new products.

-9-

Marketing and sales expenses increased by \$22,000 (11%) to \$220,000 in the third quarter of 2002 compared to Q3 01 and by \$20,000 (3%) to \$690,000 year to date, as compared to YTD 01. The increase in quarterly expenses is primarily attributable to increased advertising and trade show expenses over the same period in the prior year. Although the Company has maintained its advertising budget for the year, the timing and placement of ads from year to year has changed in an effort to broaden the potential customer base by targeting specific publications and issues. Likewise, the timing of trade shows and expenses has changed from year to year. Year to date, the overall increase in marketing and sales expense is due to employment related expenses, including increased commission expenses, resulting from the addition of a Director of Sales during the year. The Company will attend one more trade show during the remainder of the fiscal year and will continue to focus on its plan of increased print media advertising. It is expected that overall marketing and sales expenses will remain at the same level for the remainder of the fiscal year.

General and administrative expenses increased \$31,000 (12%) to \$282,000 for the third quarter of 2002 as compared to Q3 01. Year to date general and administrative expenses increased by \$39,000 (5%) to \$837,000 as compared to the same nine month period in 2001. Both the quarterly and year to date increases are mainly due to increased labor, insurance, and depreciation expenses. The increased labor expenses are due to personnel promotions and transfers within the company, whereby labor previously considered to be direct labor (cost of sales) is now considered to be general and administrative (overhead) due to the job duties involved. In addition, the company has seen dramatic increases in corporate insurance expenses during the year, accounting for approximately 33% of the year to date variance. Increased depreciation expenses are due to the installation of a new computer system during the quarter. All of the increases have been partially offset by reductions in other general and administrative expenses, as management has been able to successfully cut costs and reduce year to date expenditures for items such as travel and entertainment, office supplies, temporary labor and outside services. The Company continues to expect

Edgar Filing: ADVANCED PHOTONIX INC - Form 10QSB

that G & A expenses will remain stable throughout the remainder of the year and does not anticipate any notable fluctuations from the current level.

Acquisition investigation expenses of \$630,000 were recognized in the previous quarter in conjunction with the Company's termination of its planned merger with Jenner Biotherapies, Inc. (Jenner). The amount previously recognized was adjusted in the current quarter, as actual expenses realized were \$14,000 less than anticipated, bringing the year to date total expense to \$616,000. Approximately \$448,000 of the total expense recognized was previously reported as prepaid acquisition costs.

Interest income for the quarter was \$34,000, or \$66,000 less than Q3 01. Interest income for the year to date period was \$171,000, or \$75,000 less than the same period in the prior year. The decrease in interest income is primarily due to continually declining interest rates seen during the current year, resulting in a much lower return on capital as compared to the prior year.

Net income for the third quarter of 2002 was \$98,000, or \$27,000 lower than net income of \$125,000 reported in Q3 01. Year to date, the Company's net loss of (\$55,000) is \$399,000 lower than the net income of \$344,000 reported for the same period in the prior year. Excluding the impact of acquisition investigation expenses, net income for YTD 02 would be \$561,000, or \$217,000 higher than net income reported for YTD 01.

-10-

LIQUIDITY AND CAPITAL RESOURCES

At December 23, 2001, the Company had cash and cash equivalents of \$4.5 million, no short-term investments, and working capital of \$7.6 million. Due to declining interest rates available on securities available to the Company pursuant to its investment policy, the Company held no short-term investments at December 23, 2001. Rather, the Company was able to achieve higher yields on more liquid money market accounts and thus transferred excess available cash to such instruments.

The Company's cash, cash equivalents and short-term investments decreased by \$480,000 during the nine months ended December 23, 2001. \$3,000 was obtained through the exercise of stock options. \$76,000 was used for operating activities (before cash provided by short-term investments and including the write off of prepaid acquisition costs). Operating expenditures were affected mainly by the impact of acquisition investigation expenses and increased inventories.

Expenses of \$430,000, previously reported as prepaid acquisition costs, were expensed during the previous period as they represented costs incurred by the Company in connection with the examination of a possible business combination with Jenner Biotherapies, Inc.. The agreement was terminated in the second quarter of FY 2002 and the corresponding total expenses to date of \$616,000 (including \$430,000 of prepaid acquisition costs) have been recognized.

Raw materials and work in process inventories increased a total of \$583,000, compared to \$119,000 in the previous year, due to several contracts requiring advance expenditures for materials, engineering and production charges which are scheduled to ship throughout the remainder of the year and during the upcoming year.

\$407,000 was used for capital equipment, compared to \$100,000 during the comparable period of the prior year. Computer system upgrades (hardware and software) accounted for \$263,000 of the total capital spending; the remainder was due to expenditures required for manufacturing equipment upgrades and replacements. The Company expects that cash outlays for capital items will increase only slightly during the remainder of the year, as the computer system

Edgar Filing: ADVANCED PHOTONIX INC - Form 10QSB

upgrade is complete and there are no plans for any major machinery upgrades throughout the remainder of FY 2002.

FORWARD LOOKING STATEMENTS

The information contained herein includes forward looking statements that are based on assumptions that management believes to be reasonable but are subject to inherent uncertainties and risks including, but not limited to, unforeseen technological obstacles which may prevent or slow the development and/or manufacture of new products, limited (or slower than anticipated) customer acceptance of new products which have been and are being developed by the Company (particularly its LAAPD product line), the availability of other competing technologies and a decline in the general demand for optoelectronic products.

-11-

PART II OTHER INFORMATION

Items 1-4

None.

Item 5 Other Information

(a) The Company reported the following open market purchases of stock by insiders during the

Name	Position	Shares Purchased	Date Purcha
Richard D. Kurtz	Chairman	20,000	10/02/01
		9,000	12/14/01
		1,000	12/14/01
Brock Koren	Director,	8,500	12/19/01
	Chief Executive Officer	1,500	12/20/01
M. Scott Farese	Director	5,000	10/24/01
		5,000	11/02/01
		5,000	11/16/01
Stephen P. Soltwedel	Director	5,000	10/08/01
		5,000	01/22/02
Paul Sharman	Vice President - Operations	5,000	12/28/01

Item 6 Exhibits and Reports on Form 8-K

(a) Exhibits
None.

(b) Reports on Form 8-K
None.

-12-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Advanced Photonix, Inc.

(Registrant)

Date: February 5, 2002

/s/ Susan A. Schmidt

Susan A. Schmidt
Chief Financial Officer and Secretary

/s/ Brock Koren

Brock Koren
President & Chief Executive Officer

-13-